Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
Completed · Phase 1, Phase 2 · NCT06727058
Conditions: Influenza Immunization
At a glance
- Research payments reported, 2025
- $5.7M
- U.S. investigators named
- 14
- Sites paid
- 9
- Planned or actual enrollment
- 276
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Pandemic flu H5 mRNA vaccine (biological), Placebo (other)
- Dates
- Started 2024-12-09; completion 2026-03-24
- Results posted
- Not yet
The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participant will be approximately 13 months.
From ClinicalTrials.gov, last updated 2026-04-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $5.7M in research payments for this study in 2025 (152 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ramana K. Puppala, M.D. OB-GYN (Obstetrics & Gynecology) · Greenville, AL
- Jeffrey S. Overcash, MD Emergency Medicine · Chula Vista, CA
- James L. Andersen, M.D. Addiction Medicine · Eagle Lake, FL
- Bruce G. Rankin, D. O. Family Medicine · Deland, FL
- Shital-hiten J. Upadhyay, MD Emergency Medicine · St Petersburg, FL
- Bobby V. Khan, M.D. Cardiology · Atlanta, GA
- Kiran A. Saraiya, D.O. Nephrology (Kidney) · Warren, MI
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Charles Harper JR., MD Internal Medicine · Norfolk, NE
- Charles H. Eger, M.D Internal Medicine · Cincinnati, OH
- Kelly N. Morales, MD Family Medicine · North Charleston, SC
- Harish N. Thakkar, M.D. Internal Medicine · Sugar Land, TX
- John L. Richards, MD Family Medicine · South Jordan, UT
- James R. Clark, MD Internal Medicine · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research,inc $2.0M
- Sandhill Research, Llc $1.3M
- Quest Research Institute Llc $465,114
- University Clinical Research Dela Llc $403,021
- Olympus Clinical Research $387,396
- Velocity Clinical Research $360,004
- Coastal Carolina Research Center,incorporation $348,597
- Charlottesville Medical Research Center,llc $278,579
- The Children's Mercy Hospital, MO $60,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.